World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
136
Citations
60831
World Ranking
1996
National Ranking
1135

Peter A. Campochiaro publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Peter A. Campochiaro sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 668 publications — 78th percentile

78% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Peter A. Campochiaro D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Peter A. Campochiaro sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 136 D-Index — 90th percentile

90% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Peter A. Campochiaro is affiliated with Johns Hopkins University School of Medicine in the United States and has contributed extensively to medical research, particularly within the fields of medicine and biochemistry, genetics, and molecular biology. Their main research focus lies in ophthalmology, with a significant number of publications addressing retinal diseases, disorders, and treatments.

Their work spans multiple subfields, including ophthalmology, molecular biology, radiology, nuclear medicine, imaging, genetics, and public health. In the context of ophthalmology, their research often involves retinal diseases and treatments, retinal development and disorders, retinal imaging and analysis, glaucoma and retinal disorders, retinal and optic conditions, cell adhesion molecules research, and studies related to retinopathy of prematurity.

Peter A. Campochiaro has frequently published in notable venues such as:

  • Ophthalmology
  • The Lancet
  • Free Radical Biology and Medicine
  • JAMA Ophthalmology
  • Science Advances

They have collaborated with several researchers on multiple occasions, including primary coauthors:

  • Raquel Lima e Silva
  • Jikui Shen
  • Yogita Kanan
  • Mahmood Khan
  • Arshad M. Khanani

Among their recent publications are the following papers:

  • Sustained suppression of VEGF for treatment of retinal/choroidal vascular diseases, 2020, Progress in Retinal and Eye Research
  • Retinal vascular occlusions, 2020, The Lancet
  • The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress, 2020, Current Neuropharmacology
  • Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration, 2021, Ophthalmology
  • Gelling hypotonic polymer solution for extended topical drug delivery to the eye, 2020, Nature Biomedical Engineering

Best Publications

  • A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants

    Lars G. Fritsche;Wilmar Igl;Jessica N.Cooke Bailey;Felix Grassmann

  • Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1.

    Nicholas W. Gale;Gavin Thurston;Sean F. Hackett;Roumiana Renard

  • Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.

    David M. Brown;Peter A. Campochiaro;Rishi P. Singh;Zhengrong Li

  • Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion

    Peter A. Campochiaro;Jeffrey S. Heier;Leonard Feiner;Sarah Gray

  • Seven new loci associated with age-related macular degeneration

    Lars G. Fritsche;Lars G. Fritsche;Wei Chen;Wei Chen;Matthew Schu;Brian L. Yaspan

  • Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1

    Brian D. Kelly;Sean F. Hackett;Kiichi Hirota;Yuji Oshima

  • Two-Year Outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study

    Quan Dong Nguyen;Syed Mahmood Shah;Syed Mahmood Shah;Afsheen A. Khwaja;Roomasa Channa

  • Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study.

    David M. Brown;Peter A. Campochiaro;Robert B. Bhisitkul;Allen C. Ho

  • Sustained Delivery Fluocinolone Acetonide Vitreous Inserts Provide Benefit for at Least 3 Years in Patients with Diabetic Macular Edema

    Peter A. Campochiaro;David M. Brown;Andrew Pearson;Sanford Chen

  • VEGF is major stimulator in model of choroidal neovascularization.

    Nohoon Kwak;Naoyuki Okamoto;Jeanette M. Wood;Peter A. Campochiaro

  • Genetic variants near TIMP3 and high-density lipoprotein–associated loci influence susceptibility to age-related macular degeneration

    Wei Chen;Dwight Stambolian;Albert O. Edwards;Kari E. Branham

  • Ranibizumab for Macular Edema Due to Retinal Vein Occlusions: Long-term Follow-up in the HORIZON Trial

    Jeffrey S. Heier;Peter A. Campochiaro;Linda Yau;Zhengrong Li

  • Antioxidants reduce cone cell death in a model of retinitis pigmentosa.

    Keiichi Komeima;Brian S. Rogers;Lili Lu;Peter A. Campochiaro

  • Retinal and choroidal neovascularization.

    Peter A. Campochiaro

  • Molecular Pathogenesis of Retinal and Choroidal Vascular Diseases

    Peter A. Campochiaro

  • Blockade of Vascular Endothelial Cell Growth Factor Receptor Signaling Is Sufficient to Completely Prevent Retinal Neovascularization

    Hiroaki Ozaki;Man Seong Seo;Keiko Ozaki;Haruhiko Yamada

  • Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model

    Takao Tobe;Sagrario Ortega;Jose D. Luna;Hiroaki Ozaki

  • Genome-wide association study of advanced age-related macular degeneration identifies a role of the hepatic lipase gene (LIPC)

    Benjamin M. Neale;Jesen Fagerness;Jesen Fagerness;Robyn Reynolds;Lucia Sobrin

  • Vascular Endothelial Growth Factor Is a Critical Stimulus for Diabetic Macular Edema

    Quan Dong Nguyen;Sinan Tatlipinar;Syed Mahmood Shah;Julia A. Haller

  • Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study

    Quan Dong Nguyen;Syed Mahmood Shah;Syed Mahmood Shah;Jeffery S. Heier;Diana V. Do

Frequent Co-Authors

Donald J. Zack
Donald J. Zack Johns Hopkins University School of Medicine
Aleksander S. Popel
Aleksander S. Popel Johns Hopkins University
Justin Hanes
Justin Hanes Johns Hopkins University
Nicholas Katsanis
Nicholas Katsanis Galatea Bio Inc
Kang Zhang
Kang Zhang Macau University of Science and Technology
Stephan Ripke
Stephan Ripke Massachusetts General Hospital
Mark J. Daly
Mark J. Daly Massachusetts General Hospital
Johanna M. Seddon
Johanna M. Seddon University of Massachusetts Chan Medical School
Kevin G. Peters
Kevin G. Peters Procter & Gamble (United States)
Joseph T. Coyle
Joseph T. Coyle Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in medicine but seeking flexibility, there are several online degrees and certification programs that can help launch or advance your healthcare career. Many professionals turn to options such as the cheapest online dnp programs for an affordable pathway to a Doctor of Nursing Practice degree, ideal for those aiming for advanced nursing roles.

For pharmacy careers, some learners now consider a 3-year online pharmd to expedite their journey to becoming a licensed pharmacist. These online pharmacy doctorate programs balance accessibility with comprehensive training.

Not all medical careers require long years of study. Non-clinical roles such as health records management are growing rapidly, and a health information technology online degree can prepare you for careers in data management, compliance, or administration within healthcare settings.

For those seeking quick entry into the field, earning a coding certificate is a popular route. Understanding medical coding certification cost can help you plan your education and budget effectively.

Best Scientists Citing Peter A. Campochiaro

Trending Scientists

Recently Published Articles